Cortistatin (CST-14 / CST-17)
Cortistatin is a somatostatin-related neuropeptide existing as 14- or 17-amino acid isoforms (CST-14, CST-17). Despite sharing 11 of 14 residues with somatostatin, cortistatin is encoded by a distinct gene and exhibits unique anti-inflammatory, neuromodulatory, and sleep-promoting properties, including binding to the ghrelin receptor (GHSR-1a).
Cortistatin is a neuropeptide closely related to somatostatin, existing primarily as two isoforms: CST-14 (14 amino acids) and CST-17 (17 amino acids, the predominant human form). First identified in 1996 by de Lecea et al. in the rat cerebral cortex, cortistatin shares 11 of 14 residues with somatostatin-14 and binds all five somatostatin receptors (SSTR1–5) with comparable affinity.
Overview
Cortistatin was named for its predominant expression in the cerebral cortex ("cortex" + "statin" for its inhibitory activity). Although structurally similar to somatostatin, cortistatin has a distinct expression pattern — it is found primarily in cortical and hippocampal GABAergic interneurons, whereas somatostatin has broader CNS and peripheral distribution. The two peptides arise from separate genes through independent evolutionary duplication, and cortistatin knockout mice exhibit phenotypes distinct from somatostatin knockouts, confirming non-redundant biological roles.
A key distinguishing feature of cortistatin is its ability to bind the growth hormone secretagogue receptor (GHSR-1a), the ghrelin receptor. This interaction is not shared by somatostatin and provides cortistatin with unique neuroendocrine and metabolic signaling properties. Cortistatin has also emerged as a potent endogenous anti-inflammatory mediator, with therapeutic relevance in autoimmune and neurodegenerative disease models.
Mechanism of Action
Cortistatin exerts its effects through multiple receptor systems:
- Somatostatin receptors (SSTR1–5): Cortistatin binds all five SSTRs with affinity comparable to somatostatin, inhibiting adenylate cyclase via Gi/Go-coupled signaling. This mediates growth hormone suppression, anti-proliferative effects, and modulation of neurotransmitter release de Lecea et al. (1996).
- Ghrelin receptor (GHSR-1a): Unlike somatostatin, cortistatin binds GHSR-1a, functioning as a partial agonist. This interaction influences appetite, reward signaling, and neuroendocrine regulation, positioning cortistatin at the intersection of somatostatin and ghrelin signaling Deghenghi et al. (2001).
- MrgX2 receptor: Cortistatin activates Mas-related gene X2, a receptor not shared with somatostatin. This may mediate some of cortistatin's unique pain-modulating and immune effects Robas et al. (2003).
- Anti-inflammatory signaling: Cortistatin suppresses NF-κB-driven pro-inflammatory cytokine production (TNF-α, IL-6, IL-12) in macrophages and dendritic cells, promotes Treg generation, and inhibits Th1/Th17 differentiation through cAMP-dependent and independent pathways Gonzalez-Rey et al. (2006).
- Cortical inhibition: Cortistatin depresses cortical activity and enhances slow-wave sleep through mechanisms distinct from somatostatin, potentially involving adenosine receptor signaling and modulation of acetylcholine release.
Reconstitution Calculator
Reconstitution Calculator
Calculate your peptide dosing
Set up a clean workspace with all supplies ready.
7x / week for weeks
Research
Anti-inflammatory and Autoimmune Effects
Cortistatin has demonstrated potent anti-inflammatory activity in multiple autoimmune models. In experimental autoimmune encephalomyelitis (EAE), cortistatin treatment reduced clinical severity, demyelination, and CNS inflammatory infiltrates by suppressing encephalitogenic Th1/Th17 responses and promoting regulatory T cell generation Gonzalez-Rey et al. (2006). In collagen-induced arthritis, cortistatin reduced joint inflammation, synovial hyperplasia, and cartilage destruction with efficacy comparable to or exceeding somatostatin Gonzalez-Rey et al. (2007). In sepsis models, cortistatin improved survival and reduced multi-organ damage by suppressing inflammatory cytokine cascades Gonzalez-Rey et al. (2006).
Cortical Activity and Cognition
Cortistatin selectively depresses cortical neuronal firing rates when applied locally to cortical neurons. In hippocampal studies, cortistatin modulates long-term potentiation (LTP) and synaptic plasticity de Lecea et al. (1996). Cortistatin-deficient mice show enhanced hippocampal-dependent learning in some paradigms but also exhibit increased susceptibility to seizures, suggesting cortistatin normally balances excitatory/inhibitory tone in cortical circuits. These cognitive effects distinguish cortistatin from somatostatin, which has different effects on memory consolidation.
Ghrelin Receptor Interaction
Cortistatin's ability to bind GHSR-1a distinguishes it fundamentally from somatostatin. Through this receptor, cortistatin can modulate growth hormone secretion, appetite signaling, and reward circuits. However, cortistatin acts as a partial agonist or functional antagonist at GHSR-1a rather than a full agonist like ghrelin, potentially serving as an endogenous brake on ghrelin-driven feeding behavior and GH pulsatility Deghenghi et al. (2001). This dual receptor profile — activating both somatostatin and ghrelin receptors — makes cortistatin a unique integrator of growth, metabolic, and immune signaling.
Neurodegeneration and Alzheimer's Disease
Cortistatin levels are altered in Alzheimer's disease brain tissue, with reductions in cortistatin-expressing interneurons in the cortex and hippocampus. Given cortistatin's role in modulating cortical excitability, sleep architecture, and neuroinflammation — all disrupted in Alzheimer's — cortistatin deficiency may contribute to disease pathology. Research has shown that cortistatin administration reduces neuroinflammation and amyloid-associated pathology in preclinical models, with effects mediated through both anti-inflammatory activity and modulation of neuronal network dynamics Burgos-Ramos et al. (2008).
Sleep and EEG Effects
Cortistatin was originally characterized for its ability to induce slow-wave sleep. Intracerebroventricular administration of cortistatin in rats enhances slow-wave activity in EEG recordings and promotes non-REM sleep without affecting REM sleep architecture de Lecea et al. (1996). This effect is distinct from somatostatin, which does not promote sleep at comparable doses. The sleep-promoting mechanism may involve antagonism of cholinergic wake-promoting circuits and enhancement of adenosinergic signaling in the basal forebrain.
Safety Profile
Cortistatin has shown a favorable safety profile in preclinical studies. As a naturally occurring neuropeptide with rapid plasma degradation, toxicity at research doses has not been reported. Key considerations include:
- GH suppression: As an SSTR agonist, cortistatin can suppress growth hormone release, though this effect is transient at typical research doses.
- Sedation: Sleep-promoting effects may cause sedation, consistent with its physiological role.
- Cardiovascular: Mild hypotension has been observed in some preclinical models, consistent with vasodilatory properties.
- No clinical trial data: Cortistatin has not advanced to human clinical trials. All safety data derive from preclinical models.
- Immunosuppression: Potent anti-inflammatory effects could theoretically impair host defense in immunocompromised settings, though this has not been observed in preclinical infection models.
Pharmacokinetic Profile
Cortistatin (CST-14 / CST-17) — Pharmacokinetic Curve
Intraperitoneal, Intracerebroventricular (research)Quick Start
- Route
- Intraperitoneal, Intracerebroventricular (research)
Research Protocols
intracerebroventricular Injection
Intracerebroventricular administration of cortistatin in rats enhances slow-wave activity in EEG recordings and promotes non-REM sleep without affecting REM sleep architecture [de Lecea et al.
intraperitoneal Injection
Administered via intraperitoneal.
What to Expect
What to Expect
Rapid onset expected; half-life of ~2–5 minutes (plasma, estimated) indicates fast-acting pharmacokinetics
Due to short half-life (~2–5 minutes (plasma, estimated)), effects are expected per-dose; consistent daily administration maintains therapeutic levels
Regular administration schedule required; effects are dose-dependent and do not persist between doses
Quality Indicators
What to look for
- Human clinical trials conducted
- Well-established safety profile
- Naturally occurring compound
- Extensive peer-reviewed research base
Frequently Asked Questions
References (11)
- [10]Gonzalez-Rey E et al — Therapeutic potential of cortistatin in autoimmunity: from bench to bedside Trends Pharmacol Sci (2023)
- [1]de Lecea L, Criado JR, Prospero-Garcia O, et al A cortical neuropeptide with neuronal depressant and sleep-modulating properties Nature (1996)
- [3]Robas N, Mead E, Bhogal N MrgX2 is a high potency cortistatin receptor expressed in dorsal root ganglion J Biol Chem (2003)
- [4]Gonzalez-Rey E, Chorny A, Robledo G, Delgado M Cortistatin, a new antiinflammatory peptide with therapeutic effect on lethal endotoxemia J Exp Med (2006)
- [5]Gonzalez-Rey E, Chorny A, Del Moral RG, et al Therapeutic effect of cortistatin on experimental arthritis by downregulating inflammatory and Th1 responses Ann Rheum Dis (2007)
- [6]Burgos-Ramos E, Hervás-Aguilar A, Aguado-Llera D, et al Somatostatin and Alzheimer's disease Mol Cell Endocrinol (2008)
- [7]Gonzalez-Rey E, Fernandez-Martin A, Chorny A, Delgado M Therapeutic effect of cortistatin in experimental autoimmune encephalomyelitis Brain Behav Immun (2006)
- [2]Deghenghi R, Papotti M, Ghigo E, Muccioli G Cortistatin, but not somatostatin, binds to growth hormone secretagogue (GHS) receptors of human pituitary gland J Endocrinol Invest (2001)
- [9]Delgado-Maroto V et al — Cortistatin deficiency exacerbates intestinal inflammation and gut barrier dysfunction Br J Pharmacol (2023)
- [8]Morell M et al — Cortistatin as a novel multimodal therapy for inflammatory and neurodegenerative diseases Mol Cell Endocrinol (2022)
- [11]Souza-Moreira L et al — Cortistatin in metabolic inflammation: protective role in obesity-associated adipose tissue dysfunction Front Immunol (2022)
Cortexin
Cortexin is a complex of water-soluble neuropeptides isolated from the cerebral cortex of cattle and pigs, used clinically in Russia for neuroprotection in traumatic brain injury, ischemic stroke recovery, pediatric cognitive disorders, and age-related neurodegeneration.
CRH (Corticotropin-Releasing Hormone)
CRH is the 41-amino acid master regulator of the hypothalamic-pituitary-adrenal (HPA) axis, driving ACTH release and the cortisol stress cascade. CRH is the endocrinological designation for the same molecule known as CRF in neuroscience, with particular relevance to adrenal function, placental biology, and inflammatory conditions.